FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000413086> ?p ?o ?g. }

• W2000413086 endingPage "2553" @default.
• W2000413086 startingPage "2551" @default.
• W2000413086 abstract "Future OncologyVol. 10, No. 16 EditorialIs in vitro-acquired resistance to enzalutamide a useful model?Carlo Buonerba & Giuseppe Di LorenzoCarlo Buonerba Medical Oncology Unit, Department of Clinical Medicine, Federico II University, Naples, ItalySearch for more papers by this author & Giuseppe Di Lorenzo*Author for correspondence: E-mail Address: giuseppedilorenzoncol@hotmail.com Medical Oncology Unit, Department of Clinical Medicine, Federico II University, Naples, Italy Genitourinary Cancer Section, Università Federico II, Napoli, ItalySearch for more papers by this authorPublished Online:22 Dec 2014https://doi.org/10.2217/fon.14.212AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: abirateroneacquired resistance to the therapycabazitaxelcastration-resistant prostate cancerenzalutamideReferences1 Di Lorenzo G, Autorino R, Figg WD, De Placido S. Hormone-refractory prostate cancer: where are we going? Drugs 67(8), 1109–1124 (2007).Crossref, Medline, CAS, Google Scholar2 Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr. Drug Targets 13(13), 1676–1686 (2012).Crossref, Medline, Google Scholar3 Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 6, pii:S0140–S6736(14), 60525–60520 (2014).Google Scholar4 Ferro M, Bruzzese D, Perdonà S et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml. PLoS ONE 8(7), e67687 (2013).Crossref, Medline, CAS, Google Scholar5 Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int. 110(2 Pt 2), E99–E104 (2012).Crossref, Medline, CAS, Google Scholar6 Borsò E, Boni G, Galli L et al. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer. Future Oncol. 30, 1–9 (2014).Crossref, Google Scholar7 Buonerba C, Di Lorenzo G. Sequential therapies in castration-resistant prostate cancer. Future Oncol. 10(2), 153–155 (2014).Link, CAS, Google Scholar8 Al Nakouzi N, Le Moulec S, Albigès L et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur. Urol. doi:10.1016/j.eururo.2014 (2014) (Epub ahead of print).Medline, Google Scholar9 van Soest RJ, van Royen ME, de Morrée ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur. J. Cancer 49(18), 3821–3830 (2013).Crossref, Medline, CAS, Google Scholar10 Di Lorenzo G, Buonerba C. Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. Eur. Urol. 63(5), 961 (2013).Crossref, Medline, Google Scholar11 Efstathiou E, Titus M, Wen S et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur. Urol. doi:10.1016/j.eururo.2014.05.005 (2014) (Epub ahead of print).Google Scholar12 Di Lorenzo G, Bracarda S, Buonerba C, Aieta M, Mirone V. Poor survival in prostate cancer patients with primary refractoriness to docetaxel. Eur. Urol. 65, 505–507 (2014).Crossref, Medline, Google Scholar13 De Placido S, Rescigno P, Federico P et al. Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. World J. Clin. Cases 2, 228–231 (2014).Crossref, Medline, Google Scholar14 Buonerba C, Pond GR, Sonpavde G et al. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol. 9, 889–897 (2013).Link, CAS, Google Scholar15 Aparicio AM, Harzstark AL, Corn PG et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19(13), 3621–3630 (2013).Crossref, Medline, CAS, Google Scholar16 Lockhart AC, Sundaram S, Sarantopoulos J. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Invest. New Drugs 32(6), 1236–1245 (2014).Crossref, Medline, CAS, Google Scholar17 Buonerba C, Federico P, D'Aniello C et al. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother. Pharmacol. 67, 1455–1461 (2011).Crossref, Medline, CAS, Google Scholar18 Buonerba C, Federico P, Bosso D et al. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. Future Oncol. 10, 1353–1360 (2014).Link, CAS, Google Scholar19 Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 344(1), 1–12 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByBIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer14 March 2017 | Clinical Cancer Research, Vol. 23, No. 6 Vol. 10, No. 16 STAY CONNECTED Metrics Downloaded 125 times History Published online 22 December 2014 Published in print December 2014 Information© Future Medicine LtdKeywordsabirateroneacquired resistance to the therapycabazitaxelcastration-resistant prostate cancerenzalutamideFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2000413086 created "2016-06-24" @default.
• W2000413086 creator A5022468686 @default.
• W2000413086 creator A5064453022 @default.
• W2000413086 date "2014-12-01" @default.
• W2000413086 modified "2023-09-27" @default.
• W2000413086 title "Isin vitro-acquired resistance to enzalutamide a useful model?" @default.
• W2000413086 cites W1499815917 @default.
• W2000413086 cites W1969202480 @default.
• W2000413086 cites W1978752166 @default.
• W2000413086 cites W2000530779 @default.
• W2000413086 cites W2015582258 @default.
• W2000413086 cites W2021096047 @default.
• W2000413086 cites W2022864847 @default.
• W2000413086 cites W2038862065 @default.
• W2000413086 cites W2050630383 @default.
• W2000413086 cites W2059143306 @default.
• W2000413086 cites W2069958884 @default.
• W2000413086 cites W2078559150 @default.
• W2000413086 cites W2102624911 @default.
• W2000413086 cites W2106315111 @default.
• W2000413086 cites W2169091599 @default.
• W2000413086 cites W2248461775 @default.
• W2000413086 doi "https://doi.org/10.2217/fon.14.212" @default.
• W2000413086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25531044" @default.
• W2000413086 hasPublicationYear "2014" @default.
• W2000413086 type Work @default.
• W2000413086 sameAs 2000413086 @default.
• W2000413086 citedByCount "1" @default.
• W2000413086 countsByYear W20004130862017 @default.
• W2000413086 crossrefType "journal-article" @default.
• W2000413086 hasAuthorship W2000413086A5022468686 @default.
• W2000413086 hasAuthorship W2000413086A5064453022 @default.
• W2000413086 hasConcept C121608353 @default.
• W2000413086 hasConcept C126322002 @default.
• W2000413086 hasConcept C143998085 @default.
• W2000413086 hasConcept C2776551883 @default.
• W2000413086 hasConcept C2780192828 @default.
• W2000413086 hasConcept C29456083 @default.
• W2000413086 hasConcept C61367390 @default.
• W2000413086 hasConcept C71924100 @default.
• W2000413086 hasConceptScore W2000413086C121608353 @default.
• W2000413086 hasConceptScore W2000413086C126322002 @default.
• W2000413086 hasConceptScore W2000413086C143998085 @default.
• W2000413086 hasConceptScore W2000413086C2776551883 @default.
• W2000413086 hasConceptScore W2000413086C2780192828 @default.
• W2000413086 hasConceptScore W2000413086C29456083 @default.
• W2000413086 hasConceptScore W2000413086C61367390 @default.
• W2000413086 hasConceptScore W2000413086C71924100 @default.
• W2000413086 hasIssue "16" @default.
• W2000413086 hasLocation W20004130861 @default.
• W2000413086 hasOpenAccess W2000413086 @default.
• W2000413086 hasPrimaryLocation W20004130861 @default.
• W2000413086 hasRelatedWork W1652439388 @default.
• W2000413086 hasRelatedWork W2309274182 @default.
• W2000413086 hasRelatedWork W2414042649 @default.
• W2000413086 hasRelatedWork W2590294003 @default.
• W2000413086 hasRelatedWork W2929753048 @default.
• W2000413086 hasRelatedWork W2971490708 @default.
• W2000413086 hasRelatedWork W3023947295 @default.
• W2000413086 hasRelatedWork W3132581442 @default.
• W2000413086 hasRelatedWork W3197069188 @default.
• W2000413086 hasRelatedWork W4229076799 @default.
• W2000413086 hasVolume "10" @default.
• W2000413086 isParatext "false" @default.
• W2000413086 isRetracted "false" @default.
• W2000413086 magId "2000413086" @default.
• W2000413086 workType "article" @default.